Skip to main content

Advertisement

Table 1 Summary of efficacies and potencies of topotecan and indenoisoquinoline derivatives

From: Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant Ube3a gene associated with Angelman syndrome

Compound EC50 [M] Emax LC50 [M]
Topotecan 3.04E−08 (± 3.40E−09) 1.51 (± 0.11) 2.30E−06 (± 2.01E−08)
Indotecan 2.56E−08 (± 1.05E−09)* 1.78 (± 0.13)* 2.01E−06 (± 1.59E−07)
Indimitecan 7.47E−09 (± 7.49E−10)* 1.47 (± 0.10) 7.89E−07 (± 3.43E−08)*
DB-IV-58 3.10E−08 (± 9.75E−09) 1.45 (± 0.12) 2.01E−06 (± 1.09E−07)
DB-V-37 2.99E−08 (± 8.29E−09) 1.48 (± 0.08) 2.02E−06 (± 1.02E−07)
  1. EC50, Emax, and LC50 are estimated from data presented in Fig. 4. Significance was tested by two-way ANOVA, followed by a Bonferroni correction for multiple comparisons to determine significant differences (*p < 0.05) from topotecan-treated neurons